AbbVie banishes the ghost of Stemcentrx
Yet another ADC deal sees AbbVie buy ImmunoGen, ending a 40-year rollercoaster ride with a 100% overnight premium.
A curate’s egg for MorphoSys
Pelabresib’s Manifest-2 trial yields mixed data, but the bad part could render the whole unpalatable.
ESMO 2023 – tarlatamab hits the target for Amgen
But late-breaking data raise questions about lack of a dose response.
Three mystery phase 1 entrants
Bristol, AbbVie and Jiangsu HengRui move to enter clinical trials with undisclosed mechanisms of action.
